학술논문
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Document Type
Article
Author
Source
In: Journal of Clinical Oncology . (Journal of Clinical Oncology, 20 March 2024, 42(9):987-993)
Subject
Language
English
ISSN
15277755
0732183X
0732183X